
McKesson (MCK) Stock Forecast & Price Target
McKesson (MCK) Analyst Ratings
Bulls say
McKesson is a leading player in the US pharmaceutical wholesale industry, focused on expanding into higher-margin services and the biosimilars market while facing challenges in their RxTS segment and concerns related to opioid distribution. The company's strong financial position and investment in technology for efficiency make it a top choice, but changes in drug pricing and reimbursement models could pose risks. They are also spinning off their medical-surgical solutions segment and expanding into clinical research.
Bears say
McKesson is well-established in the competitive pharmaceutical wholesale industry, but their negative outlook is driven by potential risks such as decreasing employer coverage and rising competition from biosimilars. Additionally, while the company is prioritizing growth in certain segments, there are concerns about its sustainability efforts and plans to spin off a portion of its business. This, coupled with the company's heavy reliance on the U.S. market for revenue, warrants a negative outlook from a financial analyst's perspective.
This aggregate rating is based on analysts' research of McKesson and is not a guaranteed prediction by Public.com or investment advice.
McKesson (MCK) Analyst Forecast & Price Prediction
Start investing in McKesson (MCK)
Order type
Buy in
Order amount
Est. shares
0 shares